1	Randomized	Randomize	B-VP	VBN	O	7	NMOD	-1
2	,	,	O	,	O	7	P	-1
3	open	open	B-NP	JJ	O	4	NMOD	-1
4	label	label	I-NP	NN	O	7	NMOD	-1
5	,	,	O	,	O	7	P	-1
6	prospective	prospective	B-NP	JJ	O	7	NMOD	-1
7	study	study	I-NP	NN	O	0	ROOT	-1
8	on	on	B-PP	IN	O	7	NMOD	-1
9	the	the	B-NP	DT	O	10	NMOD	-1
10	effect	effect	I-NP	NN	O	8	PMOD	16	effect
11	of	of	B-PP	IN	O	10	NMOD	-1
12	zoledronic	zoledronic	B-NP	JJ	O	13	NMOD	-1
13	acid	acid	I-NP	NN	O	11	PMOD	-1
14	on	on	B-PP	IN	O	10	NMOD	-1
15	the	the	B-NP	DT	O	16	NMOD	-1
16	prevention	prevention	I-NP	NN	O	14	PMOD	18	prevention
17	of	of	B-PP	IN	O	16	NMOD	-1
18	bone	bone	B-NP	NN	B-protein	19	NMOD	-1
19	metastases	metastasis	I-NP	NNS	I-protein	17	PMOD	0
20	in	in	B-PP	IN	O	16	NMOD	-1
21	patients	patient	B-NP	NNS	O	20	PMOD	-1
22	with	with	B-PP	IN	O	21	NMOD	-1
23	recurrent	recurrent	B-NP	JJ	O	25	NMOD	-1
24	solid	solid	I-NP	JJ	O	25	NMOD	-1
25	tumors	tumor	I-NP	NNS	O	22	PMOD	-1
26	that	that	B-NP	WDT	O	25	NMOD	-1
27	did	do	B-VP	VBD	O	26	SBAR	-1
28	not	not	O	RB	O	27	VMOD	-1
29	present	present	B-ADJP	JJ	O	27	PRD	0
30	with	with	B-PP	IN	O	29	AMOD	-1
31	bone	bone	B-NP	NN	O	32	NMOD	-1
32	metastases	metastasis	I-NP	NNS	O	30	PMOD	0
33	at	at	B-PP	IN	O	32	NMOD	-1
34	baseline	baseline	B-NP	NN	O	33	PMOD	-1
35	.	.	O	.	O	7	P	-1

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Bisphosphonates	Bisphosphonate	B-NP	NNS	O	4	SUB	-1
4	have	have	B-VP	VBP	O	1	NMOD	-1
5	been	be	I-VP	VBN	O	4	VC	-1
6	used	use	I-VP	VBN	O	5	VC	0
7	successfully	successfully	B-ADVP	RB	O	6	VMOD	-1
8	in	in	B-PP	IN	O	6	VMOD	-1
9	the	the	B-NP	DT	O	10	NMOD	-1
10	treatment	treatment	I-NP	NN	O	8	PMOD	19	treatment
11	of	of	B-PP	IN	O	10	NMOD	-1
12	hypercalcemia	hypercalcemia	B-NP	NN	O	11	PMOD	-1
13	and	and	O	CC	O	4	VMOD	-1
14	to	to	B-VP	TO	O	15	VMOD	-1
15	reduce	reduce	I-VP	VB	O	4	VMOD	0
16	skeletal-related	skeletal-related	B-NP	JJ	O	17	NMOD	-1
17	complications	complication	I-NP	NNS	O	15	OBJ	-1
18	of	of	B-PP	IN	O	17	NMOD	-1
19	bone	bone	B-NP	NN	B-protein	20	NMOD	-1
20	metastases	metastasis	I-NP	NNS	I-protein	18	PMOD	0
21	.	.	O	.	O	1	P	-1

1	Recent	Recent	B-ADJP	JJ	O	2	AMOD	-1
2	in	in	B-ADVP	FW	O	6	AMOD	-1
3	vitro	vitro	I-ADVP	FW	O	2	AMOD	-1
4	and	and	O	CC	O	2	AMOD	-1
5	in	in	B-NP	FW	O	6	AMOD	-1
6	vivo	vivo	I-NP	FW	O	7	NMOD	-1
7	evidence	evidence	I-NP	NN	O	8	SUB	-1
8	suggest	suggest	B-VP	VBP	O	0	ROOT	-1
9	that	that	B-SBAR	IN	O	8	VMOD	-1
10	they	they	B-NP	PRP	O	11	SUB	-1
11	may	may	B-VP	MD	O	9	SBAR	-1
12	also	also	I-VP	RB	O	11	VMOD	-1
13	have	have	I-VP	VB	O	11	VC	-1
14	direct	direct	B-NP	JJ	O	15	AMOD	-1
15	antitumor	antitumor	I-NP	JJ	O	16	NMOD	-1
16	effects	effect	I-NP	NNS	O	13	OBJ	0
17	via	via	B-PP	IN	O	13	VMOD	0
18	induction	induction	B-NP	NN	O	17	PMOD	0
19	of	of	B-PP	IN	O	18	NMOD	-1
20	apoptosis	apoptosis	B-NP	NN	O	19	PMOD	0
21	,	,	O	,	O	11	P	-1
22	inhibition	inhibition	B-NP	NN	O	39	NMOD	18	inhibition
23	of	of	B-PP	IN	O	22	NMOD	-1
24	the	the	B-NP	DT	O	26	NMOD	-1
25	invasive	invasive	I-NP	JJ	O	26	NMOD	14	invasive
26	potential	potential	I-NP	NN	O	23	PMOD	0
27	of	of	B-PP	IN	O	26	NMOD	-1
28	tumor	tumor	B-NP	NN	B-cell_line	30	NMOD	-1
29	cell	cell	I-NP	NN	I-cell_line	30	NMOD	-1
30	lines	line	I-NP	NNS	I-cell_line	27	PMOD	-1
31	in	in	B-ADVP	FW	O	22	NMOD	-1
32	vitro	vitro	I-ADVP	FW	O	31	AMOD	-1
33	,	,	O	,	O	39	P	-1
34	inhibition	inhibition	B-NP	NN	O	39	NMOD	18	inhibition
35	of	of	B-PP	IN	O	34	NMOD	-1
36	angiogenesis	angiogenesis	B-NP	NN	O	35	PMOD	3	angiogenesis
37	,	,	O	,	O	39	P	-1
38	and	and	O	CC	O	39	NMOD	-1
39	reduction	reduction	B-NP	NN	O	11	VMOD	18	reduction
40	in	in	B-PP	IN	O	39	NMOD	-1
41	tumor	tumor	B-NP	NN	O	42	NMOD	-1
42	growth	growth	I-NP	NN	O	40	PMOD	4	growth
43	indirectly	indirectly	B-ADVP	RB	O	44	PMOD	-1
44	via	via	B-PP	IN	O	39	NMOD	0
45	effects	effect	B-NP	NNS	O	44	PMOD	0
46	on	on	B-PP	IN	O	45	NMOD	-1
47	accessory	accessory	B-NP	NN	B-cell_type	48	NMOD	-1
48	cells	cell	I-NP	NNS	I-cell_type	46	PMOD	-1
49	.	.	O	.	O	8	P	-1

1	This	This	B-NP	DT	O	2	SUB	-1
2	is	be	B-VP	VBZ	O	0	ROOT	-1
3	a	a	B-NP	DT	O	7	NMOD	-1
4	randomized	randomize	I-NP	VBN	O	6	AMOD	-1
5	,	,	I-NP	,	O	6	P	-1
6	open	open	I-NP	JJ	O	7	NMOD	-1
7	label	label	I-NP	NN	O	10	NMOD	-1
8	,	,	O	,	O	10	P	-1
9	prospective	prospective	B-NP	JJ	O	10	NMOD	-1
10	study	study	I-NP	NN	O	2	PRD	-1
11	that	that	B-NP	WDT	O	10	NMOD	-1
12	examined	examine	B-VP	VBD	O	11	SBAR	-1
13	the	the	B-NP	DT	O	14	NMOD	-1
14	effect	effect	I-NP	NN	O	12	OBJ	16	effect
15	of	of	B-PP	IN	O	14	NMOD	-1
16	preventive	preventive	B-NP	JJ	O	19	NMOD	-1
17	zoledronic	zoledronic	I-NP	JJ	O	19	NMOD	-1
18	acid	acid	I-NP	NN	O	19	NMOD	-1
19	treatment	treatment	I-NP	NN	O	15	PMOD	19	treatment
20	on	on	B-PP	IN	O	14	NMOD	-1
21	the	the	B-NP	DT	O	22	NMOD	-1
22	development	development	I-NP	NN	O	20	PMOD	2	development
23	of	of	B-PP	IN	O	22	NMOD	-1
24	bone	bone	B-NP	NN	B-protein	25	NMOD	-1
25	metastases	metastasis	I-NP	NNS	I-protein	23	PMOD	0
26	in	in	B-PP	IN	O	22	NMOD	-1
27	patients	patient	B-NP	NNS	O	26	PMOD	-1
28	with	with	B-PP	IN	O	27	NMOD	-1
29	recurrent	recurrent	B-NP	JJ	O	31	NMOD	-1
30	solid	solid	I-NP	JJ	O	31	NMOD	-1
31	tumors	tumor	I-NP	NNS	O	28	PMOD	-1
32	,	,	O	,	O	10	P	-1
33	without	without	B-PP	IN	O	10	NMOD	-1
34	bone	bone	B-NP	NN	O	35	NMOD	-1
35	metastases	metastasis	I-NP	NNS	O	33	PMOD	0
36	at	at	B-PP	IN	O	10	NMOD	-1
37	the	the	B-NP	DT	O	38	NMOD	-1
38	time	time	I-NP	NN	O	36	PMOD	-1
39	of	of	B-PP	IN	O	38	NMOD	-1
40	randomization	randomization	B-NP	NN	O	39	PMOD	-1
41	.	.	O	.	O	2	P	-1

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Forty	Forty	B-NP	CD	O	4	NMOD	-1
4	patients	patient	I-NP	NNS	O	16	SUB	-1
5	with	with	B-PP	IN	O	4	NMOD	-1
6	recurrent	recurrent	B-NP	JJ	O	10	NMOD	-1
7	or	or	I-NP	CC	O	10	NMOD	-1
8	metastatic	metastatic	I-NP	JJ	O	10	NMOD	0
9	advanced	advance	I-NP	VBN	O	10	NMOD	-1
10	cancer	cancer	I-NP	NN	O	5	PMOD	-1
11	,	,	O	,	O	4	P	-1
12	without	without	B-PP	IN	O	4	NMOD	-1
13	bone	bone	B-NP	NN	O	14	NMOD	-1
14	metastases	metastasis	I-NP	NNS	O	12	PMOD	0
15	,	,	O	,	O	4	P	-1
16	were	be	B-VP	VBD	O	1	NMOD	-1
17	randomized	randomize	I-VP	VBN	O	16	VC	-1
18	into	into	B-PP	IN	O	17	VMOD	-1
19	the	the	B-NP	DT	O	20	NMOD	-1
20	trial	trial	I-NP	NN	O	18	PMOD	-1
21	to	to	B-VP	TO	O	23	VMOD	-1
22	either	either	I-VP	CC	O	23	VMOD	-1
23	receive	receive	I-VP	VB	O	20	NMOD	19	receive
24	zoledronic	zoledronic	B-NP	JJ	O	25	NMOD	-1
25	acid	acid	I-NP	NN	O	28	NMOD	-1
26	or	or	O	CC	O	28	NMOD	-1
27	no	no	B-NP	DT	O	28	NMOD	-1
28	treatment	treatment	I-NP	NN	O	23	OBJ	19	treatment
29	.	.	O	.	O	1	P	-1

1	Patients	Patient	B-NP	NNS	O	2	SUB	-1
2	were	be	B-VP	VBD	O	0	ROOT	-1
3	followed	follow	I-VP	VBN	O	2	VC	-1
4	up	up	B-PRT	RP	O	3	VMOD	-1
5	until	until	B-PP	IN	O	3	VMOD	-1
6	bone	bone	B-NP	NN	O	7	NMOD	-1
7	metastases	metastasis	I-NP	NNS	O	5	PMOD	0
8	were	be	B-VP	VBD	O	2	VMOD	-1
9	established	establish	I-VP	VBN	O	8	VC	0
10	.	.	O	.	O	2	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	14	VMOD	0
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	4	NMOD	-1
4	percentage	percentage	I-NP	NN	O	14	SUB	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	patients	patient	B-NP	NNS	O	5	PMOD	-1
7	being	be	B-VP	VBG	O	6	NMOD	-1
8	bone	bone	B-NP	NN	O	9	NMOD	-1
9	metastases	metastasis	I-NP	NNS	O	7	OBJ	0
10	free	free	B-ADJP	JJ	O	9	NMOD	0
11	at	at	B-PP	IN	O	10	AMOD	-1
12	12	12	B-NP	CD	O	13	NMOD	-1
13	mo	mo	I-NP	NN	O	11	PMOD	-1
14	was	be	B-VP	VBD	O	0	ROOT	-1
15	60	60	B-NP	CD	O	16	NMOD	-1
16	%	%	I-NP	NN	O	23	NMOD	-1
17	in	in	B-PP	IN	O	16	NMOD	-1
18	the	the	B-NP	DT	O	20	NMOD	-1
19	zoledronic	zoledronic	I-NP	JJ	O	20	NMOD	-1
20	acid	acid	I-NP	NN	O	17	PMOD	-1
21	and	and	O	CC	O	23	NMOD	-1
22	10	10	B-NP	CD	O	23	NMOD	-1
23	%	%	I-NP	NN	O	14	PRD	-1
24	in	in	B-PP	IN	O	23	VMOD	-1
25	the	the	B-NP	DT	O	27	NMOD	-1
26	control	control	I-NP	NN	O	27	NMOD	0
27	group	group	I-NP	NN	O	24	PMOD	-1
28	(	(	O	(	O	33	DEP	-1
29	p	p	B-NP	NN	O	31	SUB	-1
30	less	less	B-ADJP	JJR	O	31	AMOD	-1
31	than	than	B-PP	IN	O	33	DEP	-1
32	0.0005	0.0005	B-NP	CD	O	31	AMOD	-1
33	)	)	O	)	O	14	VMOD	-1
34	,	,	O	,	O	14	P	-1
35	while	while	B-SBAR	IN	O	14	VMOD	-1
36	the	the	B-NP	DT	O	37	NMOD	-1
37	percentages	percentage	I-NP	NNS	O	41	SUB	-1
38	at	at	B-PP	IN	O	37	NMOD	-1
39	18	18	B-NP	CD	O	40	NMOD	-1
40	mo	mo	I-NP	NN	O	38	PMOD	-1
41	were	be	B-VP	VBD	O	35	SBAR	-1
42	20	20	B-NP	CD	O	43	NMOD	-1
43	%	%	I-NP	NN	O	46	NMOD	-1
44	and	and	O	CC	O	46	NMOD	-1
45	5	5	B-NP	CD	O	46	NMOD	-1
46	%	%	I-NP	NN	O	41	PRD	-1
47	respectively	respectively	B-ADVP	RB	O	46	NMOD	-1
48	(	(	O	(	O	50	DEP	-1
49	p=0.0002	p=0.0002	B-NP	NN	O	50	DEP	-1
50	)	)	O	)	O	47	AMOD	-1
51	.	.	O	.	O	14	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	4	NMOD	-1
4	results	result	I-NP	NNS	O	5	SUB	0
5	have	have	B-VP	VBP	O	25	VMOD	-1
6	shown	show	I-VP	VBN	O	5	VC	-1
7	that	that	B-SBAR	IN	O	6	VMOD	-1
8	bisphosphonates	bisphosphonate	B-NP	NNS	O	12	SUB	-1
9	as	as	B-PP	IN	O	8	NMOD	-1
10	adjuvant	adjuvant	B-NP	JJ	O	11	NMOD	-1
11	treatment	treatment	I-NP	NN	O	9	PMOD	0
12	might	might	B-VP	MD	O	7	SBAR	-1
13	be	be	I-VP	VB	O	12	VC	-1
14	useful	useful	B-ADJP	JJ	O	13	PRD	-1
15	for	for	B-PP	IN	O	14	AMOD	-1
16	the	the	B-NP	DT	O	17	NMOD	-1
17	prevention	prevention	I-NP	NN	O	15	PMOD	18	prevention
18	of	of	B-PP	IN	O	17	NMOD	-1
19	bone	bone	B-NP	NN	B-protein	20	NMOD	-1
20	metastases	metastasis	I-NP	NNS	I-protein	18	PMOD	0
21	;	;	O	:	O	25	P	-1
22	however	however	B-ADVP	RB	O	25	VMOD	-1
23	,	,	O	,	O	25	P	-1
24	there	there	B-NP	EX	O	25	SUB	-1
25	is	be	B-VP	VBZ	O	35	VMOD	-1
26	need	need	B-NP	NN	O	35	SUB	-1
27	for	for	B-PP	IN	O	26	NMOD	-1
28	blinded	blind	B-NP	VBN	O	30	NMOD	-1
29	randomized	randomize	I-NP	VBN	O	30	NMOD	-1
30	data	datum	I-NP	NNS	O	27	PMOD	-1
31	before	before	B-PP	IN	O	30	NMOD	-1
32	such	such	B-NP	PDT	O	34	NMOD	-1
33	an	an	I-NP	DT	O	34	NMOD	-1
34	approach	approach	I-NP	NN	O	31	PMOD	-1
35	would	would	B-VP	MD	O	1	NMOD	-1
36	be	be	I-VP	VB	O	35	VC	-1
37	confirmed	confirm	I-VP	VBN	O	36	VC	-1
38	.	.	O	.	O	1	P	-1

1	In	In	B-PP	IN	O	14	VMOD	-1
2	the	the	B-NP	DT	O	5	NMOD	-1
3	meantime	meantime	I-NP	NN	O	5	NMOD	-1
4	preventive	preventive	I-NP	JJ	O	5	NMOD	-1
5	use	use	I-NP	NN	O	1	PMOD	0
6	of	of	B-PP	IN	O	5	NMOD	-1
7	bisphosphonates	bisphosphonate	B-NP	NNS	O	6	PMOD	-1
8	in	in	B-PP	IN	O	7	NMOD	-1
9	patients	patient	B-NP	NNS	O	8	PMOD	-1
10	without	without	B-PP	IN	O	9	NMOD	-1
11	any	any	B-NP	DT	O	13	NMOD	-1
12	bone	bone	I-NP	NN	B-protein	13	NMOD	-1
13	metastases	metastasis	I-NP	NNS	I-protein	10	PMOD	0
14	should	should	B-VP	MD	O	0	ROOT	-1
15	not	not	I-VP	RB	O	14	VMOD	-1
16	be	be	I-VP	VB	O	14	VC	-1
17	used	use	I-VP	VBN	O	16	VC	0
18	outside	outside	B-PP	IN	O	17	VMOD	-1
19	the	the	B-NP	DT	O	20	NMOD	-1
20	scope	scope	I-NP	NN	O	18	PMOD	-1
21	of	of	B-PP	IN	O	20	NMOD	-1
22	a	a	B-NP	DT	O	24	NMOD	-1
23	clinical	clinical	I-NP	JJ	O	24	NMOD	-1
24	trial	trial	I-NP	NN	O	21	PMOD	-1
